Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID-19
Fecha
2022Language
en
Materia
Resumen
BACKGROUND: Venous thromboembolism (VTE) contributes significantly to COVID-19 morbidity and mortality. The urokinase receptor system is involved in the regulation of coagulation. Levels of soluble urokinase plasminogen activator receptor (suPAR) reflect hyperinflammation and are strongly predictive of outcomes in COVID-19. Whether suPAR levels identify patients with COVID-19 at risk for VTE is unclear. METHODS AND RESULTS: We leveraged a multinational observational study of patients hospitalized for COVID-19 with suPAR and D-dimer levels measured on admission. In 1960 patients (mean age, 58 years; 57% men; 20% Black race), we assessed the association between suPAR and incident VTE (defined as pulmonary embolism or deep vein thrombosis) using logistic regression and Fine-Gray modeling, accounting for the competing risk of death. VTE occurred in 163 (8%) patients and was associated with higher suPAR and D-dimer levels. There was a positive association between suPAR and D-dimer (β=7.34; P=0.002). Adjusted for clinical covariables, including D-dimer, the odds of VTE were 168% higher comparing the third with first suPAR tertiles (adjusted odds ratio, 2.68 [95% CI, 1.51– 4.75]; P<0.001). Findings were consistent when stratified by D-dimer levels and in survival analysis accounting for death as a competing risk. On the basis of predicted probabilities from random forest, a decision tree found the combined D-dimer <1 mg/L and suPAR <11 ng/mL cutoffs, identifying 41% of patients with only 3.6% VTE probability. CONCLUSIONS: Higher suPAR was associated with incident VTE independently of D-dimer in patients hospitalized for COVID-19. Combining suPAR and D-dimer identified patients at low VTE risk. © 2022 The Authors.
Colecciones
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
Elevated preoperative suPAR is a strong and independent risk marker for postoperative complications in patients undergoing major noncardiac surgery (SPARSE)
Chalkias A., Laou E., Kolonia K., Ragias D., Angelopoulou Z., Mitsiouli E., Kallemose T., Smith-Hansen L., Eugen-Olsen J., Arnaoutoglou E. (2022)Background: Patients undergoing major surgery are often at risk of developing postoperative complications. We investigated whether a preoperative marker of chronic inflammation, soluble urokinase plasminogen activator ... -
Soluble Urokinase Plasminogen Activator Receptor: A Biomarker for Predicting Complications and Critical Care Admission of COVID-19 Patients
Chalkias A., Mouzarou A., Samara E., Xanthos T., Ischaki E., Pantazopoulos I. (2020)The novel coronavirus infection has spread worldwide, causing a wide spectrum of clinical manifestations. Most patients develop moderate clinical illness, but a substantial number will experience severe pneumonia, which ... -
Circulating suPAR associates with severity and in-hospital progression of COVID-19
Chalkias A., Skoulakis A., Papagiannakis N., Laou E., Tourlakopoulos K., Pagonis A., Michou A., Ntalarizou N., Mermiri M., Ragias D., Bernal-Morell E., Cebreiros López I., García de Guadiana-Romualdo L., Eugen-Olsen J., Gourgoulianis K., Pantazopoulos I., Chalkias A., Skoulakis A., Laou E., Michou A., Ntalarizou N., Mermiri M., Ragias D., Tourlakopoulos K., Pagonis A., Gourgoulianis K., Pantazopoulos I., Papagiannakis N., Kampolis C., García de Guadiana-Romualdo L., Albaladejo-Otón M.D., Rodríguez Mulero M.D., Galindo Martínez M., Hernández Olivo M., Campos Rodríguez V., Cebreiros López I., Arnaldos Carrillo M., Noguera Velasco J.A., Pascual Figal D.A., Bernal-Morell E., Alcaraz García A., Alcaraz García M.J., Martínez Martínez M., Esteban-Torrella P., Sancho-Rodríguez N., Eugen-Olsen J., for the SPARCOL Investigators (2022)Background: COVID-19 disease progression is characterized by hyperinflammation and risk stratification may aid in early aggressive treatment and advanced planning. The aim of this study was to assess whether suPAR and other ...